TITLE

US extends Imvamune smallpox vaccine trials

PUB. DATE
December 2007
SOURCE
PharmaWatch: Biotechnology;Dec2007, Vol. 6 Issue 12, p4
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports on the extension of an existing contract provided by the U.S. government with Bavarian Nordic AS to include a larger Phase II study with Imvamune. The drug is the company's investigational smallpox vaccine for persons diagnosed with atopic dermatitis. According to the report, the extension of the contract will prolong the original contract to 2010 and has a value of $15 million, with most of revenue expected at the end of 2008 and beginning of 2009.
ACCESSION #
27799814

 

Related Articles

  • OTHER NEWS TO NOTE.  // BioWorld International;11/26/2008, Vol. 13 Issue 48, p2 

    This section offers news briefs on the biotechnology industries. Asterand plc has completed a placement of 4.3 million shares at 15 pence each. Bavarian Nordic A/S received a $25 million milestone payment from the U.S. government by submitting safety data from a Phase II trial of smallpox...

  • Bavarian Nordic shares rise on collaboration deal with GSK.  // PharmaWatch: Biotechnology;September 2004, Vol. 3 Issue 9, p18 

    Reports on the collaboration between Bavarian Nordic and GlaxoSmithKline on the production and marketing of Bavarian's smallpox vaccine Imvamue. Terms of the collaborative contract; Responsibility of Bavarian for development and production of Imvamune to the U.S. government under the National...

  • Other News To Note.  // BioWorld International;4/24/2013, Vol. 18 Issue 17, p3 

    The article offers biotechnology news briefs as of April 4, 2013. Addex Therapeutics SA of Switzerland released preclinical data on the study involving application of its dipraglurant to dystonia indications. Pharmaceutical company Alkermes Inc. reported Phase II study data involving the effects...

  • OTHER NEWS TO NOTE.  // BioWorld International;10/10/2007, Vol. 12 Issue 41, p2 

    The article presents news briefs on biotechnology industry as of October 2007. Ark Therapeutics Group plc has signed an agreement to out-license rights of its oxidized low density lipoprotein auto-antibody diagnostic test kit to Lab21 Ltd. Basilea Pharmaceutica Ltd. has filed for a marketing...

  • OTHER NEWS TO NOTE.  // BioWorld Today;11/8/2007, Vol. 18 Issue 218, p4 

    This section offers news briefs on the biotechnology industry as of November 8, 2007. Aeolus Pharmaceuticals Inc. reported that AEOL 10150 showed significant protection of lung tissue in animals exposed to 2-chloroethyl-ethylsulfide. AlphaRx of Canada said that Vansolin had better efficacy than...

  • Clinic Roundup.  // BioWorld Today;2/2/2011, Vol. 22 Issue 22, p2 

    This section offers news briefs related to the biotechnology industry. Aveo Pharmaceuticals Inc. has begun patient enrollment in an exploratory biomarker study of tivozanib, a Vascular endothelial growth factor (VEGF) inhibitor. Bavarian Nordic A/S has completed a trial of smallpox vaccine...

  • VACCINE REPORT.  // BioPharm International;Jul2007, Vol. 20 Issue 7, p14 

    The article offers international news briefs related to pharmaceutical biotechnology for the year 2007. Vical Inc. has introduced a cell-free manufacturing process designed to produce large quantities of vaccine. The federal government awarded a $500 million contract to Bavarian Nordic AS in...

  • OTHER NEWS TO NOTE.  // BioWorld International;9/2/2009, Vol. 14 Issue 35, p5 

    This section offers news briefs from the biotechnology sector. A million U.S. dollars has been received by Biotie Therapies Corp. of Finland for the milestone in its collaboration with Wyeth of New Jersey for the development of phosphodiesterase 10 (PDE10) inhibitors for schizoprenia. Bavarian...

  • GOVERNMENT OF CANADA PROCURES IMVAMUNE SMALLPOX VACCINE.  // Worldwide Biotech;Jan2009, Vol. 21 Issue 1, p6 

    The article reports on the contract awarded by Public Works and Government Services Canada to Bavarian Nordic in January 2009 for the delivery of Imvamune, a Modified Vaccinia Ankara (MVA)-based, third generation smallpox vaccine. As stated, the procurement will be used by the Canadian...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics